Table 2 Treatment course and toxicities among patients with relapsed/refractory lymphoma receiving modified EPIC salvage chemotherapy in Lilongwe
From: Salvage chemotherapy for adults with relapsed or refractory lymphoma in Malawi
Total (n = 21) | HIV+ (n = 13) | HIV- (n = 8) | |
|---|---|---|---|
Cycles per patient | 3 (1–6) | 3 (1–6) | 3.5 (1–6) |
Days between cycles | 28 (25–45) | 28 (25–42) | 28 (25–45) |
Etoposide dose per cycle, mg/m2 | 100 (48–104) | 99 (51–104) | 100 (48–102) |
Ifosfamide dose per cycle, mg/m2 | 1000 (482–1042) | 993 (511–1042) | 1000 (482–1019) |
Received >50% of day 15 cisplatin doses, n (%) | 2 (10%) | 1 (8%) | 1 (13%) |
Received <4 cycles, n (%) | 12 (57%) | 8 (62%) | 4 (50%) |
Progression | 11 | 7 | 4 |
Social | 1 | 1 | ― |
Any grade 3/4 neutropenia, n (%) | 19 (90%) | 11 (86%) | 8 (100%) |
Any grade 3/4 anemia, n (%) | 10 (48%) | 4 (31%) | 6 (75%) |
Any grade 3/4 thrombocytopenia, n (%) | 3 (14%) | 1 (8%) | 2 (25%) |
Any grade 3/4 renal dysfunction, n (%) | 1 (5%) | 1 (8%) | ― |
Any grade 3/4 other non-hematologic toxicity, n (%) | 8 (38%) | 4 (31%) | 4 (50%) |